Blockade of Vascular Endothelial Growth Factor (VEGF) Aggravates the Severity of Acute Graft-versus-host Disease (GVHD) after Experimental Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Recent clinical observation reported that there was a significant correlation between change in circulating vascular endothelial growth factor (VEGF) levels and the occurrence of severe acute graft-versus-host disease (GVHD)following allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the action mechanisms of VEGF in GVHD have not been demonstrated. Methods: This study investigated whether or not blockade of VEGF has an effect on acute GVHD in a lethally irradiated murine allo-HSCT model of B6 (H-2b) →B6D2F1 (H-2b/d). Syngeneic or allogeneic recipient mice were injected subcutaneously with anti-VEGF peptides, dRK6 (50μg/dose) or control diluent every other day for 2 weeks (total 7 doses). Results: Administration of the dRK6 peptide after allo-HSCT significantly reduced survival with greaterclinical GVHD scores and body weight loss. Allogeneic recipients injected with the dRK6 peptide exhibited significantly increased circulating levels of VEGF and expansion of donor CD3＋ T cells on day ＋7 compared to control treated animals. The donor CD4＋ and CD8＋ T-cell subsets have differential expansion caused by the dRK6injection. The circulating VEGF levels were reduced on day ＋14 regardless of blockade of VEGF. Conclusion: Together these findings demonstrate that the allo-reactive responses after allo-HSCT are exaggerated by the blockade of VEGF. VEGF seems to be consumed during the progression of acute GVHD in this murine allo-HSCT model.
Abstract
Background: Recent clinical observation reported that there was a significant correlation between change in circulating vascular endothelial growth factor (VEGF) levels and the occurrence of severe acute graft-versus-host disease (GVHD)following allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the action mechanisms of VEGF in GVHD have not been demonstrated. Methods: This study investigated whether or not blockade of VEGF has an effect on acute GVHD in a lethally irradiated murine allo-HSCT model of B6 (H-2b) →B6D2F1 (H-2b/d). Syngeneic or allogeneic recipient mice were injected subcutaneously with anti-VEGF peptides, dRK6 (50μg/dose) or control diluent every other day for 2 weeks (total 7 doses). Results: Administration of the dRK6 peptide after allo-HSCT significantly reduced survival with greaterclinical GVHD scores and body weight loss. Allogeneic recipients injected with the dRK6 peptide exhibited significantly increased circulating levels of VEGF and expansion of donor CD3＋ T cells on day ＋7 compared to control treated animals. The donor CD4＋ and CD8＋ T-cell subsets have differential expansion caused by the dRK6injection. The circulating VEGF levels were reduced on day ＋14 regardless of blockade of VEGF. Conclusion: Together these findings demonstrate that the allo-reactive responses after allo-HSCT are exaggerated by the blockade of VEGF. VEGF seems to be consumed during the progression of acute GVHD in this murine allo-HSCT model.
참고문헌 (30)
- Devine SM, "Recent advances in allogeneic hematopoietic stem-cell transplantation", J Lab Clin Med, 141, pp.7~32 (2003)
- Wingard JR, "Opportunistic infections after blood and marrow transplantation", Transpl Infect Dis, 1, pp.3~20 (1999)
- Takatsuka H, "Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome", Bone Marrow Transplant, 26, pp.419~426 (2000)
- American College of Chest Physicians, "definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis", Crit Care Med, 20, pp.864~874 (1992)
- Chen X, "Relative contribution of endothelial cell and polymorphonuclear neutrophil activation in their interactions in systemic inflammatory response syndrome", Arch Surg, 131, pp.1148~1153 (1996)
- Klagsbrun M, "Regulators of angiogenesis", Annu Rev Physiol, 53, pp.217~239 (1991)
- Dvorak HF, "Vascular permeability factor", vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, 1995, pp.146, 1029~1039
- Fava RA, "Vascular permeability factor", endothelial growth factor (VPF, J Exp Med, pp.1994, 180[DOI]
- Selvaraj SK, "Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor", Blood, 102, pp.1515~1524 (2003)
- Iyer S, "The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution", J Biol Chem, 276, pp.12153~12161 (2001)
- Lunn RA, "Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease", Hematology, 10, pp.107~114 (2005)
- Min CK, "Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation", BONE MARROW TRANSPLANTATION, 38(2), pp.149~156 (2006), NATURE PUBLISHING GROUP
- 고용송, "Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis", JOURNAL OF BIOLOGICAL CHEMISTRY, 275(18), pp.13588~13596, AMER SOC BIOCHEMISTRY MOLECULAR BIOLO
- Min CK, "Paradoxical effects of interleukin- 18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation", Blood, 104, pp.3393~3399 (2004)
- Asai O, "Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation", J Clin Invest, 101, pp.1835~1842 (1998)
- Cooke KR, "An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin", Blood, 88, pp.3230~3239 (1996)
- Hill GR, "Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines", Blood, 90, pp.3204~3213 (1997)
- Yoo SA, "Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes", J Immunol, 174, pp.5846~5855 (2005)
- Reddy P, "Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis", J Exp Med, 194, pp.1433~1440 (2001)
- Tsuchihashi S, "Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia", reperfusion injury, 2006, pp.168, 695~705
- Takatsuka H, "Adult respiratory distress syndrome-like disorders after allogeneic bone marrow transplantation", Transplantation, 68, pp.1343~1347 (1999)
- Takatsuka H, "Thrombotic microangiopathy following allogeneic bone marrow transplantation", Bone Marrow Transplant, 24, pp.303~306 (1999)
- Takatsuka H, "Predicting the severity of graft-versus-host disease from interleukin- 10 levels after bone marrow transplantation", Bone Marrow Transplant, 24, pp.1005~1007 (1999)
- Hill GR, "The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation", Blood, 95, pp.2754~2759 (2000)
- Holler E, "Cytokines, viruses, and graft-versus-host disease", Curr Opin Hematol, 9, pp.479~484 (2002)
- Brok HP, "Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice", J Immunol, 151, pp.6451~6459 (1993)
- Sykes M, "Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects", Blood, 83, pp.2560~2569 (1994)
- Yang YG, "Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graftversus-host disease in mice", Blood, 90, pp.4651~4660 (1997)
- Frantz S, "Innate immunity and angiogenesis", Circ Res, 96, pp.15~26 (2005)
- Neufeld G, "Vascular endothelial growth factor (VEGF) and its receptors", FASEB J, 13, pp.9~22 (1999)